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ARTICLE OPEN
Human cell-derived tissue-engineered heart valve with
integrated Valsalva sinuses: towards native-like transcatheter
pulmonary valve replacements
Sarah E. Motta1, Valentina Lintas1, Emanuela S. Fioretta 1, Petra E. Dijkman1, Matilde Putti2, Etem Caliskan3,4,
Héctor Rodriguez Cetina Biefer3,4, Miriam Lipiski5, Mareike Sauer5, Nikola Cesarovic5, Simon P. Hoerstrup1,6 and
Maximilian Y. Emmert1,3,4,6
Transcatheter valve replacement indication is currently being extended to younger and lower-risk patients. However, transcatheter
prostheses are still based on glutaraldehyde-ﬁxed xenogeneic materials. Hence, they are prone to calciﬁcation and long-term
structural degeneration, which are particularly accelerated in younger patients. Tissue-engineered heart valves based on
decellularized in vitro grown tissue-engineered matrices (TEM) have been suggested as a valid alternative to currently used
bioprostheses, showing good performance and remodeling capacity as transcatheter pulmonary valve replacement (TPVR) in
sheep. Here, we ﬁrst describe the in vitro development of human cell-derived TEM (hTEM) and their application as tissue-
engineered sinus valves (hTESVs), endowed with Valsalva sinuses for TPVR. The hTEM and hTESVs were systematically characterized
in vitro by histology, immunoﬂuorescence, and biochemical analyses, before they were evaluated in a pulse duplicator system
under physiological pulmonary pressure conditions. Thereafter, transapical delivery of hTESVs was tested for feasibility and safety in
a translational sheep model, achieving good valve performance and early cellular inﬁltration. This study demonstrates the principal
feasibility of clinically relevant hTEM to manufacture hTESVs for TPVR.
npj Regenerative Medicine            (2019) 4:14 ; https://doi.org/10.1038/s41536-019-0077-4
INTRODUCTION
Transcatheter pulmonary valve replacement (TPVR) represents a
valid option treatment for patients suffering from valvular heart
diseases.1 Current clinically approved heart valve substitutes for
TPVR consist of glutaraldehyde-ﬁxed animal-derived materials
(e.g., bovine and porcine pericardium and porcine heart valves).2
Owing to their animal origin, such substitutes are prone to
progressive structural degradation and calciﬁc degeneration,
thus requiring multiple substitutive re-interventions, which are
particularly critical for young patients.3 Decellularized human
heart valves (allografts) are considered a valid alternative to
xenoprostheses, ensuring good performance and reduced
reoperation rates.4 However, several drawbacks—such as donor
shortage, lack of long-term follow-up studies, and inability to
grow—still limit the broad clinical adoption of such prostheses.5
To solve the rising clinical need for heart valve substitutes, heart
valve tissue engineering (TE) has been proposed as a potential
solution to generate living native-analogous heart valves with
long-term regenerative and remodeling capacities.6 Introduced
>20 years ago by Langer and Vacanti, cellularized in vitro grown
tissue-engineered heart valves (TEHVs) rely on the use of
autologous, patient-speciﬁc cell sources, to create an immuno-
logically safe product.7 However, this approach has also severe
limitations by being non-scalable, not suitable for emergency,
time consuming, and affected by patient-to-patient variability in
the ﬁnal product.8–12 Hence, a way to reduce the logistical
complexity and prosthesis variability was identiﬁed in the use of
cell-free constructs with the potential to remodel and regener-
ate upon implantation.6 This led to the development of novel
in situ TE concepts, that rely on the ability of the recipient’s body
to regenerate and remodel the TEHVs once implanted
in vivo.6,13–15 Decellularization of in vitro grown tissue-
engineered matrices (TEM) has been proposed as a possible
option to provide TEHVs with in situ regenerative properties and
off-the-shelf availability, creating a clinically relevant prosthe-
sis.16–26 Decellularized TEM showed efﬁcient cell depletion as
well as matrix preservation in a comparative in vitro study,16 as
well as in several in vivo studies.16–18,21,22 Here, decellularized
TEM-based TEHVs demonstrated superior long-term function-
ality and comparable mechanical properties to cellularized
in vitro grown TEHVs. In support of this, numerous preclinical
studies have proven the regenerative properties of decellular-
ized TEM-based TEHVs, also when implanted with transcatheter
techniques in large preclinical animal models.17–22 However,
independently of the used bioengineering methodology, TEHVs
functionality is gradually lost within few months owing to cell-
mediated leaﬂet retraction.13,17,20,22–24,27 To solve this problem,
computational modeling tools have been recently applied to
TEM-based TEHVs18,28,29 to investigate the effect of
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physiological values of stress and strain on leaﬂet remodeling.
These studies suggested that TEHVs with leaﬂets characterized
by a more physiological-like belly curvature showed limited
tissue compression, and therefore reduced leaﬂet retraction
during diastole.18,28,30 By using an insert to implement such
design,18,28,29 the TEM-based TEHVs have been implanted in the
sheep model,18 demonstrating excellent long-term functionality
and reduction of the maladaptive remodeling phenomena
observed in the previous generations of TEHVs (i.e., leaﬂet
retraction and valve insufﬁciency).9,17,21,22 These results suggest
the importance of mimicking the physiological valve design to
ensure long-term performance of the prosthesis.
Currently, the so far used transcatheter TEHVs are characterized
by two major challenges: the use of xenogeneic cell sources and/
or the absence of Valsalva sinuses.9–22,27,31 Xenogeneic cell
sources (and, in particular, ovine cells) are still largely adopted
by the scientiﬁc community for the development of TEM-based
TEHVs.9,16–18,20,22,24 This, however, signiﬁcantly limits the transla-
tional potential of TEHVs, as it may result in severe immune
reactions in human recipients, as observed for decellularized
xenogeneic prostheses.32,33 The use of human cells for TEM-based
TEHVs manufacturing will considerably reduce the risks of
immunological reaction. However, only few preclinical studies
utilized human-derived cell sources for the development of
TEHVs.19,24
The sinuses of Valsalva are an anatomical feature typical of
native semilunar valves, which promotes blood vortex formation
in diastole, allowing for a progressive and active closure of the
leaﬂets and preventing the build up of abnormal stresses in the
leaﬂets.34–36 In this regard, we recently developed new sinus-
stented tissue-engineered valves (TESVs) using ovine cell sources,
which showed promising short-term performances in a technical
feasibility study in a translational sheep model.20
In the present study, we propose a new culture protocol to
produce clinically relevant off-the-shelf available valves with
integrated Valsalva sinuses and based on a human cell-derived
TEM (hTEM), the hTESVs. Human neonatal dermal ﬁbroblasts (hDF)
represent a valid cell source for producing hTESVs, because of
their easy accessibility, rapid growth, high matrix protein
production, and remodeling genes expression, which have shown
similarities to human pediatric valvular interstitial cells.19,24,37,38 In
addition, to stimulate matrix production even further,39 hDF were
cultured in the presence of different concentration of transform-
ing growth factor-β1 (TGF-β1). After in vitro characterization of the
hTEM, the most-promising protocol was selected to produce
decellularized hTESVs for TPVR. Thereafter, hTESVs functionality
was assessed in vitro using a pulse duplicator system, followed by
in vivo feasibility evaluation in a translational sheep model.
RESULTS
Inﬂuence of TGF-β1 on hTEM development
After 4 weeks of culture, hTEM cultured in presence of TGF-
β1 showed shiny neo-tissue formation and homogeneous
extracellular matrix (ECM) deposition (Fig. 1a, b).
Quantitative analyses for the content of glycosaminoglycans
(GAGs) and hydroxyproline (HYP) were performed for every hTEM
culture condition after 4 weeks (Fig. 1c, d). GAG analysis showed
comparable expression values between the control group (3.04 ±
1.75 µg/mg dry tissue) and the TGF-β1 supplemented groups
(3.22 ± 1.35 µg/mg dry tissue, 4.17 ± 1.81 µg/mg dry tissue and
3.65 ± 1.68 µg/mg dry tissue for the 10 ng/ml, 5 ng/ml and 2.5 ng/
ml TGF-β1 groups, respectively) (Fig. 1c, Supplementary Table 1).
HYP analysis revealed no signiﬁcant difference among the control
group (22.96 ± 17.02 µg/mg dry tissue) and the TGF-
β1 supplemented groups (17.36 ± 4.29 µg/mg dry tissue, 16.40 ±
7.10 µg/mg dry tissue, and 18.30 ± 6.34 µg/mg dry tissue for the
10 ng/ml, 5 ng/ml and 2.5 ng/ml TGF-β1 groups, respectively) (Fig.
1d, Supplementary Table 1).
Histological analysis was used to assess the ECM structure in the
hTEM cultured with different TGF-β1 concentrations. Hematoxylin
and Eosin (H&E) staining demonstrated a more compact and
organized neo-tissue structure in the groups supplemented with
TGF-β1, in comparison with the control group (Fig. 1e–h). Elastica
Van Gieson (VGEL) staining (Fig. 1i–l) revealed the absence of
elastic ﬁbers, while Collagen 1 (Col-1) and Collagen 3 (Col-3)
immuno-staining (Fig. 1m–t) conﬁrmed the presence of a
collagenous matrix rich in collagen type 1 and 3.
Manufacturing of hTESVs
Integration of the polyglycolic acid (PGA) scaffold within the sinus
stent was successful, and the morphology of the wall and leaﬂets
were retained after coating with poly-4-hydroxybutyrate (P4HB)
(Fig. 2a–c). After 4 weeks of in vitro culture in the bioreactor with
physical constraints, hTESVs (n= 10) showed dense, shiny, and
homogeneous ECM formation with pliable leaﬂets (Fig. 2d–f),
which was retained after the decellularization process.
In vitro characterization of hTESVs
Histological H&E analysis conﬁrmed the formation of a dense ECM
on the PGA/P4HB scaffold and the absence of cell remnants after
decellularization (Fig. 3a–d). Immunoﬂuorescence analysis
revealed the presence of both Col-3 and Col-1 (Fig. 3e).
Quantitative biochemical analyses demonstrated an overall higher
content of GAGs (6.35 ± 0.73 µg/ml) and HYP (28.78 ± 5.60 µg/ml)
for TGF-β1 supplemented hTESVs compared to the untreated
group (3.50 ± 1.13 µg/ml and 19.85 ± 1.78 µg/ml respectively for
GAGs and HYP) (Fig. 3f).
Based on previously reported protocols,13,18 hTESVs were tested
for in vitro functionality for up to 1 hour under physiologic
pulmonary hemodynamic conditions (Fig. 3g, h). Valves did not
show any sign of damage, tear, or deformation before in vitro test
(Supplementary Fig. 1A, B), after crimping (Supplementary Fig. 1C,
D), in the valve holder (Supplementary Fig. 1E, F), or after the test
(Supplementary Fig. 1G, H). Opening and closing behavior of valve
leaﬂets was normal, with full opening in systole, and complete
closure during diastole. hTESVs (n= 2) demonstrated good
performance for up to 1 hour at pulmonary pressure conditions,
without signs of central nor paravalvular regurgitation and a peak
systolic pressure of 27.85 ± 0.5 mmHg (Fig. 3g, h).
In vivo performance of hTESVs and post mortem evaluation
To demonstrate the feasibility and safety of using hTESVs as
pulmonary valve replacement, the hTESVs (n= 3) were crimped
and loaded into the delivery device before successful transapical
implantation. Contrast angiography conﬁrmed sufﬁcient valve
positioning over the native pulmonary valve, and no evidence of
central regurgitation (Fig. 4a–f, Supplementary Video 1). Bi- and
three-dimensional (2D- and 3D)-echocardiographic assessment
displayed good hTESV performance with complete coaptation and
pliable leaﬂets (Fig. 5a–f). No paravalvular leakage, central
regurgitation, or stenosis were detected, and leaﬂet motion was
normal in all animals (Fig. 5a–f). No post-operative complications
such as embolization or acute valve thrombosis occurred. After
deployment, 3D computed tomography (3D-CT) reconstruction of
the pulmonary root conﬁrmed correct hTESV positioning (Fig.
5g–i). After the planned follow-up of up to 4 hours,19,20 the
animals were euthanized and the hTESVs were harvested for post-
mortem analysis.
Post-mortem macroscopic evaluation further conﬁrmed appro-
priate positioning of the hTESVs in the pulmonary root, without
signs of stent migration, thrombus formation, leaﬂet tears, or
rupture (Fig. 6a–d). No damages associated to crimping
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Fig. 1 Qualitative evaluation of hTEM patches cultured with hDF and quantitative tissue composition after 4 weeks culture at different TGF-β1
concentrations. a Representative image of the polyglycolic acid/poly-4-hydroxybutyrate scaffold sutured onto a stainless metal ring before
in vitro culture. b Representative image of a hTEM after 4 weeks culture showing shiny neo-tissue deposition and homogeneous matrix
distribution. c GAGs content showed slightly higher amount in patches cultured at 5 ng/ml TGF-β1. d HYP content showed similar expression
values among all the different groups. e–h Representative images of H&E staining show more pronounced neo-tissue formation for hTEM
cultured with TGF-β1 in comparison with the control group. i–l VGEL staining did not show any expression of elastic ﬁbers at 4 weeks follow-
up. Col-1 m–p and Col-3 q–t deposition is enhanced in hTEM cultured in the presence of TGF-β1 (scale bars 100 μm). Dot plot graphs present
mean ± standard deviation (center line and bounds of error bars, respectively)
S.E. Motta et al.
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procedures were observed. Qualitative histological evaluations of
the explanted hTESVs allowed to assess general valve morphology
and cellular inﬁltration after 4 hours. Minimal ﬁbrin deposition was
observed on the hTESVs surface (Fig. 6a–e) and tissue structure
was well preserved. Early host cellular inﬁltration was observed in
proximity of the wall surface and in the hinge region of the hTESVs
(Fig. 6f, h, black arrows) and was predominantly characterized by
the presence of leukocytes (Fig. 6i, black asterisk) and erythrocytes
(Fig. 6k, triangle).
DISCUSSION
Transcatheter heart valve substitutes are rapidly evolving as
alternative treatment to surgical valve replacement.5,40 Never-
theless, current clinically available bioprostheses for TPVR suffer
from major drawbacks such as continuous degeneration and
structural deterioration, making them inadequate, especially for
young adults and child patients. To address this increasing clinical
need, TEHVs have been proposed as a potential solution, being
characterized by properties such as long-term durability and
regeneration capacities.5,40
Decellularized in vitro grown TEM-based valves have been
successfully applied as TPVR in numerous preclinical studies in
non-human primate and ovine models.16–22 Recently, their long-
term durability, remodeling potential, and clinical relevance have
been highlighted in a successful 1-year follow-up study.18 Never-
theless, xenogeneic cell sources have been often employed to
produce the TEM, hampering the clinical translation of such
prostheses. Recent investigations evaluated the functionality and
remodeling capacities of non-ﬁxed decellularized xenogeneic
heart valves. After promising preclinical results,41,42 such pros-
theses have advanced into a clinical setting and were implanted in
pediatric patients, resulting in severe immune reactions and fatal
failure of the prostheses,32 thus raising many concerns on their
safety.33 Therefore, the transition of culture protocols from animal-
derived to human-derived cell sources is of pivotal importance for
the safe translation of TEHVs into clinical practice.
In this context, the production of a robust human cell-derived
TEM is fundamental to ensure immediate functionality of the
TEHVs exposed to the hemodynamic loading. Here, we developed
new culture protocols using hDF, to produce a compact and
organized hTEM. Other groups previously investigated the
potential of hDF for cardiovascular TE applications.24,37,43 These
studies showed promising results in terms of functionality and
host response, including recellularization and absence of
calciﬁcations.
Based on this promising data, we here further developed
in vitro culture protocols for TEHVs with increased translational
potential.
With the addition of TGF-β1, we stimulated collagen production
and increased tissue organization in vitro.44,45 TGF-β1 is a well-
known cytokine involved in several physiological processes like
valvulogenesis,46 valve repair,47 cell proliferation, and ECM
production.44,45 Our results suggested that the supplementation
of 5 ng/ml of TGF-β1 led to increased GAGs production,
comparable HYP content, and a qualitatively denser and more
reproducible collagenous matrix in comparison with the other
tested groups. Importantly, by extending the in vitro culture time,
it will be possible to obtain a more robust matrix capable to
sustain the aortic pressure conditions.19
Clinical translation of tissue-engineered products is challenged
by many factors. To date, the large heterogeneity of culture
methods reported in literature, the risks of infection during
culture, the non-automated and non-scalable procedures, and the
disregard of xeno-free protocols still limit the advancement of
TEHVs to a clinical setting.48,49 However, although they are not yet
clinically approved in the setting of heart valves, small caliber
conduits produced with this approach, have already been
advanced into clinical application providing safe and functional
results.40,50,51 To hasten bench-to-bedside translation, it is
necessary to establish Good Manufacturing and Good Laboratory
Practices (GMP, GLP) procedures. The development of standar-
dized manufacturing processes and quality control systems, both
compliant with the International Organization for Standardization
(ISO), have to be considered in order to satisfy the technical and
Fig. 2 Manufacturing process of a hTESV. a PGA scaffold is sutured and integrated into the nitinol stent using continuous sutures. b, c PGA
scaffold is coated with 1% P4HB in tetrahydrofuran. d–e hTESVs show dense, shiny, and homogeneous tissue formation laterally d, distally e,
and proximally f, which was retained after decellularization procedure
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infrastructural requirements for the commercialization of
TEHVs.48,52
In addition, valve design has been recognized to be a key factor
in order to achieve TEHVs long-term functionality and positive
remodeling.18,28–30 In this regard, new computational modeling
studies have recently underlined that physiological-like pre-
shaping of TEHVs during in vitro culture may be a key player for
the long-term durability and functionality of such
S.E. Motta et al.
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substitutes.18,28,29 Here, we further enhanced this concept by
introducing another fundamental anatomical feature of the native
valves: the Valsalva sinuses.
The heart valve sinuses have the physiological role of actively
promote and inﬂuence the opening and closing behavior of the
leaﬂets, generate blood vortices, and consequently blood wash-
out during diastole.35,36 Through this mechanism, the Valsalva
sinuses are responsible for the decreased mechanical stress and
strain sensed by the leaﬂets, thereby distributing the hemody-
namic loading and preventing radial cusps contraction.28,36,53–56
From a clinical point of view, the importance of the Valsalva
sinuses has been described in several surgical preservation and
reconstruction procedures showing the beneﬁts that such
anatomical features bring to the patients.57–59 Despite this
knowledge, clinically available transcatheter bioprostheses do
not integrate Valsalva sinuses in their design.
Hence, based on a previously reported study from our group18
as well as others,36,55,60,61 we hypothesized that by implementing
the Valsalva sinuses in our initial valve geometry, we could favor
valve functionality and its future remodeling.
So far, only two studies have reported the implementation of
Valsalva sinuses into TEHVs.20,62 Dodge–Khatami and colleagues62
used decellularized equine valved jugular veins as TPVR in sheep,
showing promising functionality and endothelialization potential.
However, the use of non-ﬁxed xenogeneic material may represent
a signiﬁcant limitation for their future clinical translation.
In a recent proof-of-concept study, we demonstrated the
technical feasibility of using sinus-stented-TEHVs as TPVR and
showed their functionality in a short-term follow-up period (up to
16 weeks).20 However, owing to a suboptimal initial valve design,
leaﬂet retraction and valve insufﬁciency occurred over time.
To overcome this limitation, in the present study, we have
modiﬁed the valve design by (i) implementing physiological belly-
shape in the leaﬂets, (ii) increasing the coaptation area, and (iii)
using a different suturing pattern to integrate the scaffold into the
stent prior to in vitro culture. In addition, the hTESVs described
here, were manufactured with a human cell source, thereby
enhancing their clinical relevance. This resulted in successful
in vitro valve testing and in vivo functionality, with optimal valve
performance up to 4 hours follow-up in a translational FDA-
recommended ovine model without evidence of regurgitation or
stenosis. Chronic studies are however needed to conﬁrm the
remodeling potential of the newly developed hTEM as well as the
long-term functionality of the prosthesis.
Our study has several limitations. First, the number of animals
used in this study was limited, but sufﬁcient to prove the feasibility
of our approach. Second, short- (e.g., 1–3 months) and long-term
(≥6 months) follow-up are fundamental in order to assess valve
functionality and remodeling over time, even if the remodeling
potential of a similar matrix was previously conﬁrmed by
others.23,24 Compared with our previous work,20 major changes
(i.e., different cell source, different valve and leaﬂet geometry)
were applied to obtain the hTESV and, therefore, the novel valve
design needed to be tested in an acute feasibility study. Although
chronic experiments were beyond the scope of this study, they
should be addressed in the future. Third, the stress distribution on
the leaﬂets should be validated with computational modeling
tools, whereas the ﬂow patterns determined by the implemented
Valsalva sinuses should be conﬁrmed using ﬂow magnetic
resonance imaging technologies.
In conclusion, in this study we demonstrated the possibility to
develop a human cell-derived TEM for heart valve tissue
Fig. 3 In vitro characterization of the hTESVs after 4 weeks culture. a H&E staining shows the general hTESV morphology comprising a dense
collagenous matrix and the scaffold core (scale bar: 5000 μm). b–d Magniﬁcation pictures of the hinge region b, middle of the leaﬂet and wall
c, and tip of the leaﬂet d marked by the dotted rectangles in a (scale bars: 500 μm). e Immunoﬂuorescence staining shows the presence of
Collagen 3 (green) and Collagen 1 (red) ﬁbers in the newly formed matrix (scale bars: 100 μm). f Quantitative tissue composition demonstrates
the slightly higher amount of GAGs and HYP in hTESV cultured in presence of 5 ng/ml TGF-β1 (white points) in comparison with control hTESV
(black points). g Sequence of the opening and closing behavior of hTESVs tested in a valve pulse duplicator system for 1 hour at pulmonary
pressure conditions. h Pressure and ﬂow values for a representative hTESV after 1 hour in vitro valve testing; in the left panel, blue and red
indicate pulmonary pressure and ventricular pressure, respectively; in the right panel, red indicates ﬂow rate over time. Dot plot graphs
present mean ± standard deviation (center line and bounds of error bars, respectively)
Fig. 4 Transapical hTESV delivery under ﬂuoroscopy guidance. a Imaging of the native pulmonary root. b, c Insertion and alignment of the
delivery system to the implantation site. d, e Controlled positioning and deployment of the hTESV. f Final evaluation of the deployed hTESV
conﬁrming sufﬁcient positioning and good valve functionality
S.E. Motta et al.
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engineering applications. In addition, we proposed a novel valve
design, which includes the anatomical feature of the Valsalva
sinuses, and we showed the feasibility and safety of TPVR using an
off-the-shelf available human cell-derived TESVs in an
ovine model.
METHODS
In vitro manufacturing and culture of hTEM
Scaffold patches (n= 36, triplicates) (area= 6 cm2) were produced using
non-woven PGA meshes (Conﬂuent) and coated with 1% P4HB (TEPHA
Inc.) in liquid tetrahydrofuran (Sigma-Aldrich). Scaffolds were then sutured
onto stainless steel rings (Hasler) and sterilized in ethanol following
previously reported protocols.63
Neonatal hDF (from three different donors, mycoplasma free) were
purchased from CellSystems Biotechnologie GmbH and expanded in
advanced Dulbecco’s Modiﬁed Eagle Medium (Sigma-Aldrich) supplemen-
ted with 10% fetal bovine serum (Invitrogen AG), 1% Glutamax (Invitrogen
AG), and 1% Penicillin–Streptomycin (Invitrogen AG), and cultured in a cell
incubator at 37 °C. Afterwards, cells (1.0 × 106 cells/cm2) were seeded onto
the patches using ﬁbrin as cell carrier.64
After seeding, patches were cultured at 37 °C on an orbital shaker. Tissue
culture medium was supplemented with L-ascorbic acid two-phosphate
(0.25mg/ml; Sigma-Aldrich) and medium was replaced every 2–3 days. In
addition, to investigate the role of TGF-β1 on ECM production, patches
were also supplemented with different concentrations of TGF-β1
(Peprotech): control (0 ng/ml TGF-β1), 2.5 ng/ml TGF-β1, 5 ng/ml TGF-β1,
and 10 ng/ml TGF-β1 (n= 9 per group). After 4 weeks of culture, hTEM
were decellularized by using a detergent solution (0.25% Triton X-100,
sodium deoxycholate and 0.02% ethylenediaminetetraacetic acid) fol-
lowed by a Benzonase treatment (EMD Millipore), as previously
described.16
In vitro tissue analyses of hTEM
Quantiﬁcation of GAGs and HYP (as an indicator for collagen content)
amounts were performed, as previously described,65,66 for every hTEM-
patch cultured at the different TGF-β1 conditions (n= 36). In brief, samples
were digested using a buffer solution containing 6mM papain (Sigma-
Aldrich) at 60 °C overnight. Subsequently, GAGs amount was compared
with shark cartilage chondroitin sulfate (10mg/ml, Sigma-Aldrich) as
previously described.65 Finally, HYP amount was compared with a HYP
standard solution (10mg/ml, Sigma-Aldrich) following a previously
established protocol.66 All samples were reproduced as triplicates. All
concentrations were normalized to the total dry weight of the samples.
Representative hTEM were analyzed qualitatively for matrix composition
using histology and immunohistochemistry (Ventana Benchmark) techni-
ques. Brieﬂy, hTEM were formalin-ﬁxed, parafﬁn-embedded, and cut
consecutively into 5 µm slices. The tissue sections were analyzed using
H&E, Col-1 (Abcam, ab34710, 1:200), Col-3 (Abcam, ab7778, 1:250), and
VGEL staining. The stained samples were imaged with brightﬁeld
microscopy (Mirax Midi Microscope, Carl Zeiss GmbH) and analyzed with
Pannoramic Viewer software (3DHISTECH).
Fig. 5 Echocardiographic assessment of valve functionality in vivo. a–f 2D images of hTESV show good leaﬂet motion during systole a–c and
diastole d–f. b, e 2D-Doppler of hTESV demonstrates absence of anomalies in the forward ﬂow, no regurgitation nor paravalvular leakage. c, f
3D representation of hTESV showing proper leaﬂet mobility during systole c and diastole f. g–i 3D-CT reconstruction performed pre-
operatively shows the adult sheep heart and the valve implantation site from a proximal g, distal h, and lateral i perspective, conﬁrming the
correct positioning of the hTESV in the right ventricular outﬂow tract, over the native valve. AV= aortic valve, MV=mitral valve
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Manufacturing and in vitro culture of hTESVs
Trileaﬂet sinus-shaped heart valve scaffolds (n= 10) were fabricated by
adapting a previously described protocol,17 using non-woven PGA
scaffolds, sewn to radially self-expandable sinus-shaped nitinol stents
(stent diameter: 28 mm distal, 35 mm mid-part, and 30mm proximal;
CARAG AG) by using continuous sutures (Yavo, polyvinylidene diﬂuoride,
non-resorbable, 6/0 USP). Previously developed TESVs20 were grown onto
a straight nitinol stent and then carefully readapted and sewn onto a
nitinol sinus stent. Here, we developed a novel scaffold design by creating
custom-made molds to obtain valve walls and leaﬂets that are compatible
with the sinus stent. Speciﬁcally, the new lower walls were speciﬁcally
designed to ﬁt the sinus-stent proﬁle, and leaﬂet length was increased to
provide a longer coaptation area, as previously described.18 Thereafter, the
scaffold was coated with 1% P4HB (TEPHA Inc.) in liquid tetrahydrofuran
(Sigma-Aldrich), dried overnight, and sterilized in ethanol, following
previously reported protocols.63
After hDF expansion in medium, 1.0 × 106 cells/cm2 were seeded onto
the sinus-stented heart valve scaffolds using ﬁbrin as cell carrier.64 After
seeding, tissue culture inserts were introduced as physical constraints for
the leaﬂets and the valves were then cultured into the Diastolic Pulse
Duplicator bioreactor system for 4 weeks.63 The valve housings of the
bioreactor were custom-designed to ﬁt the size of the sinus stent. Medium
was supplemented with L-ascorbic acid 2-phosphate (0.25mg/ml; Sigma-
Aldrich) and TGF-β1 (5 ng/ml, Peprotech). An additional control valve was
cultured without the addition of TGF-β1. Medium was replaced every
2–3 days. After 4 weeks of culturing, hTESVs were decellularized as
previously described.16
In vitro tissue analyses and in vitro performance of hTESVs
GAGs and HYP contents were analyzed for hTESVs cultured with and
without TGF-β1 (n= 1 for both conditions) as previously described for
hTEM.65
hTESVs were analyzed qualitatively for matrix composition using
histology (H&E) and immunoﬂuorescence. Samples of the leaﬂets were
ﬁxed in formalin and processed as previously described for hTEM.
Immunoﬂuorescence was utilized to conﬁrm the presence of Col-1 and
Col-3 proteins on a non-implanted valve. In brief, hTESVs sections were
formalin-ﬁxed, parafﬁn-embedded, and cut consecutively into 5 µm slices.
Primary antibodies for Col-1 (Abcam, ab23446, 1:200) and Col-3 (Abcam,
ab7778, 1:250) were applied followed by the relative secondary antibodies
(Lifetechnologies, Thermo Fisher Scientiﬁc, A11004 and A11008 for Col-1
and Col-3, respectively, 1:400). The stained sections were visualized using a
ﬂuorescence slide scanner (ZEISS Axio Scan.Z1, Carl Zeiss AG). Image
processing was performed using the Leica Las X Life Science imaging
software (Leica Microsystems).
hTESVs functionality was tested and visualized in a hydrodynamic
pulsatile test system (HDT-500, BDC Laboratories) as previously
described,29 using a high-speed camera (MotionScope M-5). For this
purpose, a newly developed customized silicon annulus mold comprising
apposite pockets for the sinus-shaped stent was used as valve holder.
hTESVs cultured with TGF-β1 (n= 2) and without TGF-β1 (n= 1) were
exposed to physiologic pulmonary pressure conditions for 1 hour (peak
systolic pressure of 27mmHg; end-diastolic pressure of 10mmHg; 72
bpm). Measures for peak systolic pressure and regurgitation fraction were
obtained for each valve after 10 minutes and 1 hour of tests.
Delivery system and crimping procedure
A custom-made hydraulic delivery system was designed and manufactured
by CARAG AG to enable transapical delivery of hTESVs. The system
comprised a 14 mm-stainless steel capsule (valve chamber) to accom-
modate the valve, and a ﬂexible delivery catheter.20 Previously developed
crimping device and tools20 were used to allow the crimping and insertion
of the hTESVs into the valve chamber. Delivery tests were performed on all
hTESVs (n= 3) prior implantation.
Fig. 6 Post-mortem macroscopical and histological evaluation of hTESVs after 4 hours follow-up. All three hTESVs were correctly positioned at
the entrance of the pulmonary root without signs of stent migration. Representative images of the H&E staining were performed on the valve
cross-section. a, b Correct positioning of the hTESV conﬁrmed by the presence of native leaﬂets entrapped in the stent struts. c, d hTESV
showing thrombus-free smooth surfaces and absence of tears or ruptures. e H&E staining shows retained valve morphology after 4 hours
in vivo follow-up (scale bar: 5000 μm). f–h H&E staining of the region marked by the dotted rectangles in e (1–3) shows host cellular inﬁltration
predominantly at the surface and in the hinge region of the hTESVs (black arrows) (scale bars: 200 μm). i–k 60X magniﬁcation pictures of
region marked by the dotted rectangles in f–h present an organized and packed collagenous matrix together with inﬁltrated leukocytes
(black asterisks, I) and erythrocytes (triangle, k) (scale bars: 25 μm). p= polymer remnants
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In vivo transcatheter implantation of hTESVs
The animal study was conducted at the Division of Surgical Research based
at the University Hospital of Zurich, and all animals received humane care
in accordance with the “Principles of laboratory animal-care” and the
“Guide for the care and use of laboratory animals” of the National Institutes
of Health. All the procedures received the approval of the Cantonal
Veterinary Ofﬁce (License number ZH_041_2017) and performed in
accordance with the European Union guidelines (86/609/EEC) and Swiss
Federal animal protection law and ordinance.
To evaluate the feasibility and safety, the acute performance of hTESVs
as TPVR was tested in three sheep (female white alpine sheep, 50–55 kg)
selected based on their annulus size (25.9 ± 0.2 mm at peak systolic
pressure). The animals underwent surgery through anterolateral–thoracic
access and antegrade approach at the third intercostal space. After mini-
thoracotomy and pericardiotomy, the right ventricular apex was punctured
with two purse-string sutures, and the delivery system was inserted under
ﬂuoroscopy (ALLURA FD 20/20., Philips Electronics). A baseline contrast
angiography was performed to assess the native pulmonary valve and
root. After correct positioning of the device, the valve was released under
ﬂuoroscopy guidance.
Planned follow-up for all animals (n= 3) was up to 4 hours after
implantation. Transesophageal echocardiography (TEE; Philips Healthcare
iE33W xMATRIX Ultrasound) and angiography were performed immedi-
ately after deployment and before euthanization, to assess hTESVs
functionality. The study did not include randomization or blind
investigator.
Valve positioning and acute functionality
2D- and 3D-TEE were performed immediately after implantation (n= 3) to
evaluate the performance of the hTESVs. The following parameters were
determined: oriﬁce diameter, degree of regurgitation, and leaﬂets motion.
To conﬁrm sufﬁcient hTESV positioning, the pulmonary root was imaged
and reconstructed using 3D-CT (Siemens) analysis, before and after
implantation (n= 1).
Post-mortem evaluation
After euthanization, the heart was harvested and the hTESVs (n= 3) were
macroscopically examined for tissue integrity and then processed using
histological analysis (Ventana Benchmark) to assess matrix composition
and cellular inﬁltration. Samples of the leaﬂets were ﬁxed in formalin and
processed as previously described for hTEM and hTESVs. The tissue
sections were analyzed using H&E staining.
Statistics
GAGs, and HYP content quantiﬁcation are expressed as mean ± standard
deviation, obtained by averaging the mean value of each patch for each
group. To compare the groups, unpaired non-parametric Kruskal-Wallis
test with Dunn’s correction was performed, considering the non-Gaussian
distribution of the data. p < 0.05 was considered as statistically signiﬁcant.
Statistics was elaborated with Prism software (v. 7, GraphPad).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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